

Innovative Biomarkers of Cardiovascular Complications Associated With Second-generation Bruton Tyrosine Kinase Inhibitor Treatments: a Single-center Cohort Study

NCT07174141

Status RECRUITING
Sponsor Centre Hospitalier Universitaire Dijon
Enrollment 100 participants

Key Eligibility Criteria

Inclusion (4)

- Patients eligible for treatment with second-generation Bruton's tyrosine kinase inhibitors in hematology (acalabrutinib, zanubrutinib)
- Patients aged 18 years and older
- Patients who have given their free and informed written consent to participate in this study after receiving information (or the patient's representative if the patient is unable to express consent themselves).
- Patients with a life expectancy estimated by the hematologist in charge of the patient to be greater than one year

Exclusion (8)

- Persons not affiliated with or not covered by a social security system
 - Patients subject to legal protection measures (guardianship, trusteeship)
 - Patients subject to judicial protection measures
 - Pregnant women, women in labor, or breastfeeding women
 - Prior treatment with Bruton's tyrosine kinase inhibitors (ibrutinib, acalabrutinib, zanubrutinib)
- ... and 3 more (see full listing online)

Locations (1 total)

CHU Dijon Bourgogne, Dijon, France